CEACAM5 and colorectal carcinoma: The experimental design is schematically presented in Fig. 5A. Significantly stronger and rapid inhibition of tumor progression was observed in the CART-CEA.sBsAb-treated group compared with that of the CART-CEA.sPD-1- and CART-CEA.sTREM2 scFv-treated CRC mice, as indicated by fluorescence intensity measurements (Fig. 5B-C).